Isoniazid (Laniazid, Nydrazid), also known as isonicotinylhydrazine (INH), is an organic compound that is the first-line antituberculosis medication in prevention and treatment. It was first discovered in 1912, and later in 1951 it was found to be effective against tuberculosis by inhibiting its mycolic acid (wax coat).
Isoniazid is never used on its own to treat active tuberculosis because resistance quickly develops. Isoniazid also has an antidepressant effect, and it was one of the first antidepressants discovered. Isoniazid can also be used in the treatment of a BCG-oma.
The compound was first synthesised in the early 20th century, but its activity against tuberculosis was first reported in the early 1950s and three pharmaceutical companies attempted unsuccessfully to simultaneously patent the drug (the most prominent one being Roche, who launched their version, Rimifon, in 1952). With the introduction of isoniazid, a cure for tuberculosis was first considered reasonable.
Isoniazid is available in tablet, syrup, and injectable forms (given intramuscularly or intravenously). Isoniazid is available worldwide, is inexpensive and is generally well tolerated. It is manufactured from isonicotinic acid, which is produced from 4-methylpyridine.
Although isoniazid has actions that can be considered antidepressant (the so-called "psychic energizers"), it is important to point out that in contrast to closely related agents such as iproniazid which are MAOIs, isoniazid does not inhibit MAO. Keeping this in mind, it has been suggested that the MAO inhibiting action of MAOIs may be secondary to some other more fundamental explanation that can be used to rationalize their observed utility in the treatment of depression.
This is particularly true in the case of hydrazides. However, this property remains undefined, although it does still seem pertinent to emphasize that isoniazid is not believed to inhibit MAO even though it does possess properties that are considered antidepressant.
Umang Pharmatech equipments used for production of Isoniazid Pellets:
Drug Layering, Fluid Bed Dryer, Fluid Bed Coater, Sifter & Blender, Extruder and Twin spheronizer.
Systematic (IUPAC) Name
* All transactions are carried out in conformity with patent laws applicable in the user country. Active pharmaceutical ingredients or formulations thereof will not be supplied in countries where the same is under patent protection except as and if permitted under law of the country for research and development purposes only.